Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.2050 (-0.1%) ($5.2050 - $5.2050) on Fri. Mar. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.3% (three month average) | RSI | 37 | Latest Price | $5.2050(-0.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.1% a day on average for past five trading days. | Weekly Trend | ADAP declines -0.1% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) PCY(94%) ARKG(75%) KWEB(74%) IBB(43%) ACES(42%) | Factors Impacting ADAP price | ADAP will decline at least -2.15% in a week (0% probabilities). URA(-36%) DIA(-36%) EWP(-31%) SDY(-18%) SPLV(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.15% (StdDev 4.3%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-7.83(-250.43%) | Resistance Level | $5.44 | 5 Day Moving Average | $5.3(-1.79%) | 10 Day Moving Average | $5.31(-1.98%) | 20 Day Moving Average | $5.44(-4.32%) | To recent high | -23.9% | To recent low | 3.5% | Market Cap | $805m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |